Media
View our latest materials to follow our progress in tackling respiratory diseases.
Latest Videos
View all videos
Filters
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission planned for 1H 2023
Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-1 Trial of Nebulized Ensifentrine for COPD
LONDON and RALEIGH, N.C., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it will report top-line Phase 3 data from its ENHANCE-1 trial of nebulized
Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Access to up to $400 million expected to provide cash runway through at least 2025 Top-line Phase 3 ENHANCE-1 data expected around the end of 2022 Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA)
Verona Pharma Announces November 2022 Investor Conference Participation
LONDON and RALEIGH, N.C., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will participate in the following conferences in November 2022: Stifel 2022 Healthcare Conference Date: Tuesday, November 15, 2022 Time:
Verona Pharma to Report Third Quarter 2022 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the third quarter ended September 30,
Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance
Non-dilutive capital finances planned launch of ensifentrine for COPD LONDON and RALEIGH, N.C., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces it has entered into a debt financing facility (“debt facility”) providing the Company with with access to up to $150 million from Oxford Finance LLC (“Oxford”).
Verona Pharma
Investor Information
© Verona Pharma plc 2023. All rights reserved
Ensifentrine (RPL554): Mechanism of action
Ensifentrine is a Phase 3, first-in-class candidate for the maintenance treatment of COPD.